These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26501825)

  • 1. Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.
    Sandström M; Ilan E; Karlberg A; Johansson S; Freedman N; Garske-Román U
    EJNMMI Phys; 2015 Dec; 2(1):24. PubMed ID: 26501825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized dosimetry of
    Carter LM; Ocampo Ramos JC; Kesner AL
    Biomed Phys Eng Express; 2021 Aug; 7(5):. PubMed ID: 34271565
    [No Abstract]   [Full Text] [Related]  

  • 3. Kidney dosimetry in 777 patients during
    Sandström M; Freedman N; Fröss-Baron K; Kahn T; Sundin A
    EJNMMI Phys; 2020 Dec; 7(1):73. PubMed ID: 33296054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation exposure of the spleen during (177)Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume.
    Svensson J; Hagmarker L; Magnander T; Wängberg B; Bernhardt P
    EJNMMI Phys; 2016 Dec; 3(1):15. PubMed ID: 27491429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric implications of kidney anatomical volume changes in
    Khan J; Rydèn T; Van Essen M; Svensson J; Grudzinski J; Bernhardt P
    EJNMMI Phys; 2024 Aug; 11(1):71. PubMed ID: 39090481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dosimetry procedure for organs-at-risk in
    Marin G; Vanderlinden B; Karfis I; Guiot T; Wimana Z; Reynaert N; Vandenberghe S; Flamen P
    Phys Med; 2018 Dec; 56():41-49. PubMed ID: 30527088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney dosimetry during
    Sandström M; Garske-Román U; Johansson S; Granberg D; Sundin A; Freedman N
    Acta Oncol; 2018 Apr; 57(4):516-521. PubMed ID: 28920501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized radiation dosimetry for PRRT-how many scans are really required?
    Freedman N; Sandström M; Kuten J; Shtraus N; Ospovat I; Schlocker A; Even-Sapir E
    EJNMMI Phys; 2020 May; 7(1):26. PubMed ID: 32394075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of calculation method on kidney dosimetry in
    Heikkonen J; Mäenpää H; Hippeläinen E; Reijonen V; Tenhunen M
    Acta Oncol; 2016; 55(9-10):1069-1076. PubMed ID: 27219529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE.
    Gupta SK; Singla S; Thakral P; Bal CS
    Clin Nucl Med; 2013 Mar; 38(3):188-94. PubMed ID: 23412597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative post-therapeutic dosimetry between 2D planar-based and hybrid-based methods for personalized Lu-177 treatment.
    Handayani W; Chantadisai M; Phromphao B; Noipinit N; Pasawang P; Khamwan K
    Ann Nucl Med; 2024 Jul; ():. PubMed ID: 39023826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate.
    Sandström M; Garske U; Granberg D; Sundin A; Lundqvist H
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):212-25. PubMed ID: 19727718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simplified dosimetry for kidneys and tumors in
    Ardenfors O; Nilsson JN; Thor D; Hindorf C
    EJNMMI Phys; 2022 Jun; 9(1):44. PubMed ID: 35723797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for [Formula: see text]Lu-DOTATATE therapy.
    Vergnaud L; Giraudet AL; Moreau A; Salvadori J; Imperiale A; Baudier T; Badel JN; Sarrut D
    EJNMMI Phys; 2022 May; 9(1):37. PubMed ID: 35575946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Retention of 177Lu/177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging.
    Gleisner KS; Brolin G; Sundlöv A; Mjekiqi E; Östlund K; Tennvall J; Larsson E
    J Nucl Med; 2015 Jul; 56(7):976-84. PubMed ID: 25999429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
    Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized kidney dosimetry in
    Hou X; Zhao W; Beauregard JM; Celler A
    Phys Med Biol; 2019 Aug; 64(17):175004. PubMed ID: 31456584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During
    Hagmarker L; Svensson J; Rydén T; van Essen M; Sundlöv A; Gleisner KS; Gjertsson P; Bernhardt P
    J Nucl Med; 2019 Oct; 60(10):1406-1413. PubMed ID: 30902877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management.
    Chicheportiche A; Ben-Haim S; Grozinsky-Glasberg S; Oleinikov K; Meirovitz A; Gross DJ; Godefroy J
    EJNMMI Phys; 2020 Jan; 7(1):5. PubMed ID: 31975156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.